Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

PhII Trial Panitumumab, Nivolumab, Ipilimumab in Kras/Nras/BRAF Wild-type MSS Refractory mCRC

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03442569
Recruitment Status : Recruiting
First Posted : February 22, 2018
Last Update Posted : May 23, 2019
Sponsor:
Collaborators:
Amgen
Bristol-Myers Squibb
Information provided by (Responsible Party):
UNC Lineberger Comprehensive Cancer Center

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : December 14, 2020
Estimated Study Completion Date : December 14, 2023